References
- Marler JR, Goldstein LB. Stroke–tPA and the clinic. Science 2003;301:1677.
- Wardlaw JM, Sandercock PA, Berge E. Thrombolytic therapy with recombinant tissue plasminogen activator for acute ischemic stroke: where do we go from here. A cumulative meta-analysis. Stroke 2003;34:1437–42.
- Subirós N, Del Barco DG, Coro-Antich RM. Erythropoietin: still on the neuroprotection road. Ther Adv Neurol Disord 2012;5:161–73.
- Leist M, Ghezzi P, Grasso G, et al. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 2004;305:239–42.
- Villa P, Bigini P, Mennini T, et al. Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. J Exp Med 2003;198:971–75.
- Iwai M, Cao G, Yin W, et al. Erythropoietin promotes neuronal replacement through revascularization and neurogenesis after neonatal hypoxia/ischemia in rats. Stroke 2007;38:2795–2803.
- Nguyen AQ, Cherry BH, Scott GF, et al. Erythropoietin: powerful protection of ischemic and post-ischemic brain. Exp Biol Med 2014. ( Epub ahead of print).
- Dang S, Liu X, Fu P, et al. Neuroprotection by local intra-arterial infusion of erythropoietin after focal cerebral ischemia in rats. Neurol Res 2011;33:520–28.
- Yang Y, Estrada EY, Thompson JF, et al. Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat. J Cereb Blood Flow Metab 2007;27:697–709.
- Liu K, Sun T, Wang P, et al. Effects of erythropoietin on blood-brain barrier tight junctions in ischemia-reperfusion rats. J Mol Neurosci 2013;49:369–79.
- Longa EZ, Weinstein PR, Carlson S, et al. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 1989;20:84–91.
- Belayev L, Alonso OF, Busto R, et al. Middle cerebral artery occlusion in the rat by intraluminal suture. Neurological and pathological evaluation of an improved model. Stroke 1996;27:1616–23.
- Biegel D, Spence DD, Pachter JS. Isolation and culture of human brain microvessel endothelial cells for the study of blood–brain barrier properties in vitro. Brain Res 1995;692:183–89.
- Zhao BQ, Tejima E, Lo EH. Neurovascular proteases in brain injury, hemorrhage and remodeling after stroke. Stroke 2007;38(2 Suppl):748–52.
- Woitzik J, Schilling L. A new method for superselective middle cerebral artery infusion in the rat. J Neurosurg 2007;106:872–78.
- Spatz, M. Past and recent BBB studies with particular emphasis on changes in ischemic brain edema. Acta Neurochir Suppl 2010;106:21–27.
- Lakhan SE, Kirchgessner A, Tepper D, et al. Matrix metalloproteinases and blood–brain barrier disruption in acute ischemic stroke. Front Neurol 2013;4:32.
- Yang Y, Estrada EY, Thompson JF, et al. Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat. J Cereb Blood Flow Metab 2007;27:697–709.
- Rogers DC, Campbell CA, Stretton JL, et al. Correlation between motor impairment and infarct volume after permanent and transient middle cerebral artery occlusion in the rat. Stroke 1997;28:2060–65.
- Chan CY, Chen YS, Lee HH, et al. Erythropoietin protects post-ischemic hearts by preventing extracellular matrix degradation: role of Jak2-ERK pathway. Life Sci 2007;81:717–23.
- Kadri Z, Maouche-Chretien L, Rooke HM, et al. Phosphatidylinositol 3-kinase/Akt induced by erythropoietin renders the erythroid differentiation factor GATA-1 competent for TIMP-1 gene transactivation. Mol Cell Biol 2005;25:7412–22.